ArticleBMC medical informatics and decision making2025
Circulating CCN6/WISP3 in type 2 diabetes mellitus patients and its correlation with insulin resistance and inflammation: statistical and machine learning analyses.
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.Antioxidants (Basel, Switzerland) · 2026Review
- Osteoarthritis and dementia: contrasting disorders driven by mutual pathways of autophagy, mTOR, GLP-1, AMPK, Wnt, and WISP1.Expert review of clinical pharmacology · 2026Review
- Running out the clock: Circadian rhythm dysfunction in cognitive disease.International review of neurobiology · 2026Review
- Cannabis and Cannabidiol: Pioneering Treatment for the Nervous System with Alzheimer's Disease and Peripheral Organ Involvement with Nonalcoholic Fatty Liver Disease (NAFLD).Current neurovascular research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionCellular Communication Network Factor 6 (CCN6) is an adipokine whose production undergoes significant alterations in metabolic disorders. Given the well-established link between obesity-induced adipokine dysfunction and the development of insulin resistance and type 2 diabetes mellitus (T2DM), this study investigates the potential role of CCN6 as a biomarker for T2DM. The present study aimed to investigate the association between serum CCN6 levels and T2DM, as well as its risk factors, for the first time.
methodsIn this case-control study, a total of 80 individuals diagnosed with T2DM and 80 healthy control individuals, who referred to Shariati hospital (Tehran, Iran), were included in the study. Biochemical parameters including fasting blood glucose (FBG), aspartate transaminase (AST), alanine transaminase (ALT), triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were determined using the AutoAnalyzer instrument. The circulating levels of CCN6, adiponectin, Tumor necrosis factor-α (TNF)-α, Interleukin 6 (IL-6), and insulin were quantified using ELISA. The Student t-test was applied to data that presented as mean ± standard deviations (SD). Moreover, the Gini Index was utilized to determine the weight of each factor in T2DM classification. Additionally, various machine learning models were employed to develop classifiers for predicting T2DM.
resultsT2DM patients demonstrated significantly lower levels of CCN6 (1259.76 ± 395.02 pg/ml) compared to controls (1979.17 ± 471.99 pg/ml, P < 0.001), as well as lower levels of adiponectin (P < 0.001) and higher levels of TNF-α and IL-6 (P < 0.001) compared to non-T2DM individuals. In the T2DM group, CCN6 exhibited negative correlations with insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), body mass index (BMI), IL-6, and TNF-α. Logistic regression analysis indicated an increased risk of T2DM, with a CCN6 cutoff value of 1527.95 pg/mL distinguishing T2DM patients with 86.3% sensitivity and 73.8% specificity. The Gini Index highlighted that HOMA-IR, IL6, and CCN6 had the highest weighting on T2DM.
conclusionOur research identified a significant and negative association between serum CCN6 levels and the likelihood of T2DM, as well as inflammation biomarkers (IL-6 and TNF-α). CCN6 shows promise as a potential biomarker for T2DM; however, further investigations are necessary to validate this finding and assess its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.